Europe Malaria Treatment Market Forecast to 2030 - Regional Analysis - by Treatment, Route of Administration, and Distribution Channel

List of Tables

The Europe malaria treatment market was valued at US$ 451.69 million in 2022 and is expected to reach US$ 3,060.97 million by 2030; it is estimated to grow at a CAGR of 27.0% from 2022 to 2030.

Extending Pipeline of New Drugs and Vaccines Drives Europe Malaria Treatment Market

Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.

A few antimalarial that are under clinical development are mentioned in the table below:

Table 1. Malaria Drugs/Vaccine/Compounds Under Clinical Development

Drug Developer Clinical Trial Stage

Artefenomel Sanofi Phase IIb

KAE609 Novartis AG Phase IIb

KAF156 Novartis AG Phase IIb

DSM265 Takeda Pharmaceutical Company Phase IIa

SANARIA PfSPZ-GA1 Sanaria Phase II

SANARIA PfSPZ Vaccine - Radiation Attenuated PfSPZ Vaccine Sanaria Phase II

SANARIA PfSPZ-CVac Sanaria Phase II

MSP3-CRM-Vac4All Vac4All Phase I

Liver-Stage Antigen-3 (LSA3) Vac4All Phase IIa

Source: Company Website, The Insight Partners Analysis

Therefore, the growing number of antimalarial and drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

Europe Malaria Treatment Market Overview

According to a surveillance report by ECDC, France reported the highest number of malaria cases in 2020. In 2020, France reported 1,007 confirmed malaria cases. Nearly all the cases reported by EU/EEA countries in 2020 were diagnosed in people traveling to France from other countries; these mostly included individuals linked to travel routes from West Africa. In France, P. falciparum is responsible for almost all severe cases and deaths in travelers. Many research organizations are working toward developing new approaches to eliminate malaria in France. For example, teams at the Institut Pasteur are dedicated to malaria research aiming to develop vaccines. This research is vital in finding new ways of fighting malaria. The Institute Pasteur is also taking part in a major European program named EVIMalaR, which involves 17 research institutes and universities from 7 European countries, and partners from 3 African countries. Such collaborative efforts toward malaria elimination are driving the growth of the malaria treatment market in France.

Europe Malaria Treatment Market Revenue and Forecast to 2030 (US$ Million)

Europe Malaria Treatment Market Segmentation

The Europe malaria treatment market is segmented based on treatment, route of administration, distribution channel, and country. Based on treatment, the Europe malaria treatment market is segmented into generic drugs, originators, vaccines, and others. The generic drugs segment held the largest market share in 2022.

In terms of route of administration, the Europe malaria treatment market is bifurcated into oral and parenteral. The oral segment held a larger market share in 2022.

By distribution channel, the Europe malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022.

Based on country, the Europe malaria treatment market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. France dominated the Europe malaria treatment market share in 2022.

Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, and Lupin Ltd are some of the leading players operating in the Europe malaria treatment market.

Product Code: TIPRE00025038

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights - Malaria

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Malaria Treatment Market - Key Industry Dynamics

4.1 Key Market Drivers:
- 4.1.1 Increasing Prevalence of Malaria
4.2 Market Restraints
- 4.2.1 Availability of Counterfeit Antimalarial Drugs Followed by Subsequent Drug Resistance
4.3 Market Opportunities
- 4.3.1 Growing Strategic Initiatives by Market Players
4.4 Future Trends
- 4.4.1 Extending Pipeline of New Drugs and Vaccines
4.5 Impact Analysis

5. Malaria Treatment Market - Europe Market Analysis

5.1 Europe Malaria Treatment Market Revenue (US$ million), 2022 - 2030

6. Europe Malaria Treatment Market - Revenue and Forecast to 2030 - by Treatment

6.1 Overview
6.2 Europe Malaria Treatment Market Revenue Share, by Treatment 2022 & 2030 (%)
6.3 Vaccines
- 6.3.1 Overview
- 6.3.2 Vaccines Market Revenue and Forecast to 2030 (US$ Mn)
6.4 Generic Drugs
- 6.4.1 Overview
- 6.4.2 Generic Drugs Market Revenue and Forecast to 2030 (US$ Mn)
6.5 Originators
- 6.5.1 Overview
- 6.5.2 Originators Market Revenue and Forecast to 2030 (US$ Mn)
6.6 Others
- 6.6.1 Overview
- 6.6.2 Others Market Revenue and Forecast to 2030 (US$ Mn)

7. Europe Malaria Treatment Market - Revenue and Forecast to 2030 - by Route of Administration

7.1 Overview
7.2 Europe Malaria Treatment Market Revenue Share, by Route of Administration 2022 & 2030 (%)
7.3 Oral
- 7.3.1 Overview
- 7.3.2 Oral: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Parenteral
- 7.4.1 Overview
- 7.4.2 Parenteral: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Malaria Treatment Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 Europe Malaria Treatment Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Direct Tender
- 8.3.1 Overview
- 8.3.2 Direct Tender: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Hospital Pharmacies
- 8.4.1 Overview
- 8.4.2 Hospital Pharmacies: Malaria Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Retail Pharmacies
- 8.5.1 Overview
- 8.5.2 Retail Pharmacies: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Online Pharmacies
- 8.6.1 Overview
- 8.6.2 Online Pharmacies: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.7 Others
- 8.7.1 Overview
- 8.7.2 Others: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Malaria Treatment Market - Country Analysis

9.1 Europe Malaria Treatment Market, Revenue and Forecast to 2030
- 9.1.1 Overview
  - 9.1.1.1 Europe: Malaria Treatment Market, by Countries
  - 9.1.1.2 France
  - 9.1.1.3 Overview
    - 9.1.1.3.1 France: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.1.3.2 France: Malaria Treatment Market, by Treatment
    - 9.1.1.3.3 France: Malaria -Malaria Treatment Market, by Route of Administration
    - 9.1.1.3.4 France: Malaria Treatment Market, by Distribution Channel
    - 9.1.1.3.4.1 France: Malaria Treatment Market, by Hospital Pharmacies
    - 9.1.1.3.4.2 France: Malaria Treatment Market, by Retail Pharmacies
  - 9.1.1.4 UK
  - 9.1.1.5 Overview
    - 9.1.1.5.1 UK: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.1.5.2 UK: Malaria Treatment Market, by Treatment
    - 9.1.1.5.3 UK: Malaria -Malaria Treatment Market, by Route of Administration
    - 9.1.1.5.4 UK: Malaria Treatment Market, by Distribution Channel
    - 9.1.1.5.4.1 UK: Malaria Treatment Market, by Hospital Pharmacies
    - 9.1.1.5.4.2 UK: Malaria Treatment Market, by Retail Pharmacies
  - 9.1.1.6 Italy
  - 9.1.1.7 Overview
    - 9.1.1.7.1 Italy: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.1.7.2 Italy: Malaria Treatment Market, by Treatment
    - 9.1.1.7.3 Italy: Malaria -Malaria Treatment Market, by Route of Administration
    - 9.1.1.7.4 Italy: Malaria Treatment Market, by Distribution Channel
    - 9.1.1.7.4.1 Italy: Malaria Treatment Market, by Hospital Pharmacies
    - 9.1.1.7.4.2 Italy: Malaria Treatment Market, by Retail Pharmacies
  - 9.1.1.8 Germany
  - 9.1.1.9 Overview
    - 9.1.1.9.1 Germany: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.1.9.2 Germany: Malaria Treatment Market, by Treatment
    - 9.1.1.9.3 Germany: Malaria -Malaria Treatment Market, by Route of Administration
    - 9.1.1.9.4 Germany: Malaria Treatment Market, by Distribution Channel
    - 9.1.1.9.4.1 Germany: Malaria Treatment Market, by Hospital Pharmacies
    - 9.1.1.9.4.2 Germany: Malaria Treatment Market, by Retail Pharmacies
  - 9.1.1.10 Spain
  - 9.1.1.11 Overview
    - 9.1.1.11.1 Spain: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.1.11.2 Spain: Malaria Treatment Market, by Treatment
    - 9.1.1.11.3 Spain: Malaria -Malaria Treatment Market, by Route of Administration
    - 9.1.1.11.4 Spain: Malaria Treatment Market, by Distribution Channel
    - 9.1.1.11.4.1 Spain: Malaria Treatment Market, by Hospital Pharmacies
    - 9.1.1.11.4.2 Spain: Malaria Treatment Market, by Retail Pharmacies
  - 9.1.1.12 Rest of Europe
  - 9.1.1.13 Overview
    - 9.1.1.13.1 Rest of Europe: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.1.13.2 Rest of Europe: Malaria Treatment Market, by Treatment
    - 9.1.1.13.3 Rest of Europe: Malaria -Malaria Treatment Market, by Route of Administration
    - 9.1.1.13.4 Rest of Europe: Malaria Treatment Market, by Distribution Channel
    - 9.1.1.13.4.1 Rest of Europe: Malaria Treatment Market, by Hospital Pharmacies
    - 9.1.1.13.4.2 Rest of Europe: Malaria Treatment Market, by Retail Pharmacies

10. Malaria Treatment Market Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Malaria Treatment Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Cipla Ltd
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Sun Pharmaceutical Industries Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Sanofi SA
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 GSK Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novartis AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Pfizer Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Service
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Lupin Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms